论文部分内容阅读
目的:评价多沙唑嗪、非那雄胺和西地那非联合治疗BPH相关的LUTS和ED的有效性和安全性。方法:采用双盲、随机、安慰剂对照的临床研究,84例患者随机分入A、B、C组,A组服用多沙唑嗪、非那雄胺和安慰剂,B组服用多沙唑嗪、安慰剂和西地那非,C组服用多沙唑嗪、非那雄胺和西地那非。16周后比较各组的IIEF-5、IPSS、Qmax、夜尿次数和残余尿等,并记录不良反应。结果:A、B、C组的IIEF-5分别提高10.2%、57.1%和57.6%,IPSS分别降低22.2%、20.8%和20.1%。18例(21.4%)患者有较轻的不良反应。结论:多沙唑嗪、非那雄胺和西地那非联合治疗BPH相关的LUTS和ED是安全有效的。
PURPOSE: To evaluate the efficacy and safety of doxazosin, finasteride and sildenafil in the treatment of BPH-related LUTS and ED. METHODS: A double-blind, randomized, placebo-controlled clinical study of 84 patients randomized to Groups A, B and C, Group A with doxazosin, finasteride and placebo, Group B with doxazosin Triazine, placebo and sildenafil, and group C took doxazosin, finasteride and sildenafil. After 16 weeks, the IIEF-5, IPSS, Qmax, the number of nocturia and residual urine in each group were compared, and the adverse reactions were recorded. Results: The levels of IIEF-5 in group A, B and C increased by 10.2%, 57.1% and 57.6%, respectively, and IPSS decreased by 22.2%, 20.8% and 20.1% respectively. Eighteen patients (21.4%) had mild adverse reactions. CONCLUSIONS: Doxazosin, finasteride and sildenafil are safe and effective in the treatment of BPH-related LUTS and ED.